• Title/Summary/Keyword: thromboembolism

Search Result 352, Processing Time 0.029 seconds

Pulmonary Involvement in Behcet's Disease -A Case Report- (폐동맥류를 동반한 Behcet's Disease)

  • 백효채
    • Journal of Chest Surgery
    • /
    • v.27 no.5
    • /
    • pp.402-406
    • /
    • 1994
  • Behcet`s disease is a rare systemic disease of unknown cause and it is a progressive disorder with episodes of activity and remission. The major features are oral and genital ulceration and skin and eye lesions. Pulmonary involvement is rare, and we have experienced a 38 year old female patient who had undergone right lower lobe lobectomy due to extensive, rapidly growing pulmonary thromboemboli and pseudoaneurysm in pulmonary artery.

  • PDF

Long-Term Results of Double Mitral and Aortic Valve Replacement (승모판과 대동맥판 중복치환환자의 장기임상성적)

  • 김종환
    • Journal of Chest Surgery
    • /
    • v.24 no.6
    • /
    • pp.541-546
    • /
    • 1991
  • The Ionescu-Shiley bovine pericardial xenograft valve was the most common cardiac substitute valve at Seoul National University Hospital. Since the follow-up extended for longer than 10 years, a total of and consecutive 107 patients with double mitral and aortic valve replacement using this valve from May 1979 to June 1984 were studied for the long-term clinical results. Their ages were 34.0$\pm$11.9 years at surgery, and eight patients died within 30 days of surgery with operative mortality rate of 7.5%. Ninety-nine early survivors were followed up for a total of 488.1 patient-years[Mean$\pm$SD, 4.9$\pm$2.7 years], and nine died with the linearlized late mortality rate of 1.84% /patient-year[pt-yr]. They experienced major complications: thromboembolism, 0.615% /pt-yr bleeding, 0.205% /pt-yr; endocarditis, l. 639%/pt-yr; overall valve failure, 6.146% /pt-yr; and primary tissue failure, 1.639%/ pt-yr. The actuarial survival rates were 91.4$\pm$2.9% and 89.6$\pm$3.4% at postoperative 5 and 10 years, and the probability of freedom from thromboembolism was 95.8$\pm$2.5% at 10 years. The primary tissue failure began to occur from postoperative 6 years and the probabilities of freedom from structural valve failure were 80.2$\pm$7.9% and 62.3$\pm$12.7% at 8 and 10 years after surgery respectively. Although there was increasing number of patients with valve tissue failure after 6 years, the evidence of expected premature and accelerated valve degeneration among young population was not clear on the age-related analysis. And, no definite cumulative patient groups beyond the various age limits could be suggested for or against the use of this valve.

  • PDF

Clinical Experience of Abdominal Aortic Aneurysm (복부 대동맥류의 임상적 경험)

  • Gu, Bon-Il;O, Sang-Jun
    • Journal of Chest Surgery
    • /
    • v.28 no.3
    • /
    • pp.263-267
    • /
    • 1995
  • A total and consecutive 87 patients underwent aortic valve replacement[AVR with the St. Jude Medical prosthesis between 1984 and 1993. Age ranged from 14 to 66 years[mean:38.6$\pm$ 14.0 years .Twenty-one patients [24.1% had undergone previous valve replacement. There were 8 early deaths with an operative mortality rate of 9.2% [7.6% for primary AVR and 14.3 % for re-replacement AVR . Seventy-nine early survivors were,followed for a total of 309.1 patient-years[mean:3.9$\pm$ 2.5 years . A late mortality rate was 5.1% [4 patients or a linearized incidence of 1.294 %/patient-year. All were anticoagulated with coumadin to maintain the international normal ized ratio[INR between 1.5 and 2.5. One patient experienced thromboembolism[0.324%/patient-year , and none did bleeding. Endocarditis occurred in one[0.324%/patient-year . Paravalvular leak was the most frequent complication and was experienced by 8 patients[2.588%/patient-year , and 5 of them required re-replacement AVR[1.618 %/patient year of reoperation rate . There was no structural failure of the prosthesis. Actuarial survival including operative death was 83.9%$\pm$ 4.6% at 10 years.The actuarial estimates of freedom from thromboembolism and of freedom from late death and all complications were 95.1% $\pm$ 4.8 % and 81.4% $\pm$ 6.1%, respectively, at 10 years. These clinical results suggest that less intensive anticoagulation may be allowed for patients of AVR with the St. Jude Medical valve with low incidences of both thromboembolic and bleeding complications.

  • PDF

Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension in a Patient with Antiphospholipid Syndrome and Systemic Lupus Erythematosus (항인지질 증후군과 전신성 홍반성 루푸스 환자에게 발생된 만성 폐혈전색전성 폐동맥 고혈압에 대해 시행한 혈전내막제거술)

  • Kang, Pil-Je;Kim, Jeong-Won;Lee, Jae-Won
    • Journal of Chest Surgery
    • /
    • v.40 no.12
    • /
    • pp.867-870
    • /
    • 2007
  • Antiphospholipid syndrome (APS) is defined as venous and/or arterial thromboses, recurrent fetal losses, thrombocytopenia in combination with repeatedly positive tests for the lupus anticoagulant (LAC), and anticardiolipin antibodies (aCL). The pulmonary manifestation is APS are relatively rare. We report a rare case of antiphopholipid syndrome with systemic lupus erythematosus in a patient who presented with pulmonary hypertension secondary to a chronic pulmonary thromboembolism. A bilateral thromboendarterectomy was performed satisfactorily and the incision was extended to the left intrapleural pulmonary artery.

Clinical Results of the Mechanical Cardiac Valves (기계판막의 임상적 평가)

  • 박창권
    • Journal of Chest Surgery
    • /
    • v.24 no.2
    • /
    • pp.161-170
    • /
    • 1991
  • Clinical results with the Mechanical cardiac valves were reviewed for 261 patients who underwent cardiac valve replacement from September, 1985 to July, 1990. of the Mechanical valves used, 156 were Carbomedics, 109 Duromedics, 52 St. Jude and 11 Bjork-Shiley. Overall hospital mortality was 14 out of 261[5,36%]: 9 out of 159[5.66%] for MVR, 1 out of 35[2.86%] for AVR and 4 out of 67[5.96%] for DVR[AVR+MVR]. Two hundred and forty seven operative survivors were followed up for a total 466.8 patient-years, ranged from 1 month to 4.9 years [a mean 1.8 years] and the follow up was 96.0%. There were 12 valve-related complications: three from thromboembolism, three from valve thrombosis, three from prosthetic valve endocarditis, two from paravalvular leak and the other one from hemorrhage. Actuarial rate free from all valve-related complication at 4.9 years was 96$\pm$1.3%. There were 11 late deaths: two from thromboembolism, one from valve thrombosis, one from prosthetic valve endocarditis, one from hemorrhage and the others 6 from non-valve-related complications. Actuarial survival rate at 4.9 years was 94$\pm$2.0%. 96$\pm$3.0% for MVR, 94$\pm$4.2% for AVR and 91$\pm$3.7% for DVR[AVR+MVR]. And there are 7 reoperations: three from paraprosthetic leak, two from prosthetic valve endocarditis and two from valve thrombosis. Actuarial rate free from reoperation at 9 years was 96$\pm$2.9%. On the basis of this 4.9 years of experience, the pyrolytic carbon mechanical valves appears to be an excellent mechanical prosthesis for cardiac valve replacement, in terms of hemodynamic performance, low mortality and low thrombogenecity.

  • PDF

Thromboembolic Complications After Ionescu Shiley Valve Replacement: Seven Years* Experience (IonescuShiley 조직판막 이식수술후 발생한 혈전전색증에 관한 연구 -7년간의 장기성적-)

  • Na, Myung-Hoon;Chae, Hurn;Suh, Kyung-Phil
    • Journal of Chest Surgery
    • /
    • v.20 no.1
    • /
    • pp.48-54
    • /
    • 1987
  • This report provides follow-up data on 557 patients [73 aortic, 357 mitral, and 127 multiple valve replacements] undergone lonescu-Shiley pericardial Xenograft valve replacement at Seoul National University Hospital between January, 1979 and December, 1985. There were 35 early death [6.3%] and 522 operative survivors were observed, and the cumulative follow-up is 1,140 patient-years [mean: 2.18 years per patient] The thromboembolic complications occurred in 34 cases [3.0% per patient-year] and the rate was 2.1% per patient-year for mitral and 0.3% per patient-year for aortic valve replacement in the presence of anticoagulation therapy. Among the 34 embolic episodes, 9 patients were dead [0.8% per patient-year] and the cause of death were 5 cerebral thromboembolism, 2 pulmonary embolism, and 2 intracerebral hemorrhage due to inappropriate anticoagulation after thromboembolic episode. Actuarial probability [+ SEM] of remaining free of thromboembolism for AVR is 88.1 x 11.1% at 5 years, for MVR 79.1 a 13.4% at 7 years and for multiple valve replacement 77.2 e 5.21% at 7 years. The incidence rate of thromboembolic complications after AVR is not less than that of MVR [0.3 Among the potential thromboembolic risk factors, atrial fibrillation is possible risk factor to increase the thromboembolic complication [0.05 < P < 0.1], but the importance of other factors, such as atrial clot, large left atrial size, mitral position, NYHA functional class, and age is less definite. A careful follow-up and the proper control of anticoagulation without omission, poor control, and arbitrary withdrawal is important for the successful management of the thromboembolic complications and the anticoagulation-related morbidity and mortality.

  • PDF

A comparative study on anticoagulants following valve replacement surgery - a retrospective study with warfarin anticoagulation comparing with antiplatelet therapy in patients with bioprosthetic heart valve replacement (판막 이식수술후의 각종 항응고제 사용에 관한 비교적 연구 - 조직판막 이식수술후 Warfarin 사용군과 antiplatelet 사용군과의 비교 -)

  • Chae, Hurn;Park, Young-Kwan;Suh, Kyung-Phill
    • Journal of Chest Surgery
    • /
    • v.20 no.1
    • /
    • pp.13-21
    • /
    • 1987
  • To clarify the difference between the outcome of warfarin anticoagulation and the antiplatelet [Aspirin, Dipyridamole] therapy after bioprosthetic heart valve replacement, we compared the following two groups. Group I [Warfarin group] consisted of 557 patients undergone lonescu - Shiley valve replacement between January, 1979 and December, 1985, and treated with scheduled warfarin therapy at Seoul National University Hospital. Group II [Antiplatelet group] consisted of 128 patients undergone lonescu - Shiley, Carpentier - Edwards or Wessex bioprosthetic valve replacement between March, 1983 and December, 1986, and treated primarily with antiplatelet therapy [Aspirin plus Dipyridamole] at SeJong General Hospital. The two groups were similar with respect to age, number of valves utilized per patient, type of operation and risk factors of thromboembolism. In group I, 522 patients excluding 35 hospital death [hospital mortality 6.3%], and in group II, 119 survivors excluding 9 hospital death [hospital mortality 7.0%] were followed. In group I, there were 13 fatal complications, of which seven were thromboembolic [0.6% / pt-yr] and six hemorrhagic [0.5%/pt-yr] during the period of four years. In group II, there were 3 fatal thromboembolic complications [2.3%/pt-yr] during the period of four years. This showed no statistically significant difference. Apart from fatal complications, there were lots of warfarin related minor complications in group I comparing with those of group II. The actuarial probability of the freedom from thromboembolism and of the freedom from fatal complications were very similar at each corresponding years postoperatively. As a result, warfarin anticoagulation in patients with bioprosthetic valve replacement did not reveal any significant advantages over antiplatelet therapy.

  • PDF

Effect of Sambutang on the Serum Cholesterol Levels and the Cardiovascular System in Experimental Animals (삼부탕(蔘附湯)이 실험동물(實驗動物)의 혈장지질함량(血漿脂質含量) 및 심혈관계(心血管系)에 미치는 영향(影響))

  • Choi, Cheol-Won;Shin, Sun-Ho;Moon, Byung-Soon
    • The Journal of Internal Korean Medicine
    • /
    • v.18 no.1
    • /
    • pp.97-113
    • /
    • 1997
  • The present experiment was designed to investigate the effects of Sambutang water extracts on the serum cholesterol levels and the cardiovascular system in the experimental animals. Thus, the changes of blood pressure and heart rate were measured after oral administration. Measurment of Mortality rate was observed for measuring the effect of Sambutang water extract. Sambutang water extract against pulmonary thromboembolism induced by collagen the mixture(0.1 ml/10 g, 2 mg/kg) plus serotonin(5 mg/kg) in mouse. The effect of Sambutang water extract was examined by observing the change of collagen-induced platelet aggregation, coagulation activity, ex vivo and in vitro fibrinolytic activity of euglobulin fraction in rats. The results were summarized as follows. 1. Sambutang decreased the serum cholesterol levels in rats. 2. Sambutang dropped the blood pressure in spontaneous hypertensive rat. 3. The drug increased the auricular blood flow in rabbit. 4. The drug relaxed the artery contraction by pretreated norepinephrine in rat. 5. The drug inhibited the death rate of mouse which was led to thromboembolism by serotonin and collagen. 6. The drug inhibited the platelet aggregation in rat. 7. The drug prolonged the prothrombin time and activated partial thromboplastin time on the test of plasma coagulation factor activity in rat, but was not valuable. 8. The drug increased the antithrombin activity in rat and the fibrinogen lysis time was reduced and lysis area was increased. 9. Sambutang reduced fibrinogen lysis time of rat in vitro assay. According to the above mentioned results. Sambutang increased the blood flow and dropped the blood pressure by the dilation of blood vessel. And the drug presented the antithrombin activity, inhibited the platelet aggregation.

  • PDF